Experimental cell therapy for Hard-to-Treat cancers hits early snag
NCT ID NCT05868915
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new treatment called HV-101 for people with advanced solid tumors that had spread or come back. The therapy uses a patient's own immune cells (TILs) taken from their tumor, grown in a lab, and then given back along with chemotherapy and IL-2. The study was terminated after enrolling only 1 person, so we have very limited information on safety or effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HV-101 (tumor-infiltrating lymphocyte cells) plus chemotherapy (fludarabine, cyclophosphamide) and IL-2
What this could lead to
If successful, this approach could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong
This was a very early, small trial (only 1 participant enrolled) that was terminated, so we have very little data. TIL therapy can cause serious side effects from the chemotherapy and immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Renmin Hospital of Wuhan University
Wuhan, Hubei, 430060, China